OncoMatch/Clinical Trials/NCT05762419
FUS Etoposide for DMG
Is NCT05762419 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Etoposide; Oral, 50 Mg for diffuse intrinsic pontine glioma.
Treatment: Etoposide; Oral, 50 Mg — The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator controlled sonication is a non-invasive method of temporarily opening up the blood brain barrier to allow a greater concentration of the drug to reach into the brain tumor. This may improve response and may also reduce system side effects in the patient. The primary purpose of this study is to evaluate the feasibility of safely opening the blood brain barrier in children with progressive diffuse midline gliomas (DMG) treated with oral etoposide using focused ultrasound with microbubbles and neuro-navigator-controlled sonication. For the purpose of the study, the investigators will be opening up the blood brain barrier temporarily in one or two locations around the tumor using the non-invasive focused ultrasound technology, and administrating oral etoposide in children with progressive diffuse midline glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Biomarker criteria
Allowed: H3F3A (H3 K27M) K27M mutation
histological confirmation of H3K27M mutation of pontine or thalamic glioma
Prior therapy
Cannot have received: etoposide (etoposide)
Subjects that have previously received etoposide therapy
Lab requirements
Blood counts
Peripheral absolute neutrophil count ≥ 1,500/µL; Platelet count ≥ 100,000/µL; PTT and APTT within normal institutional limits
Kidney function
Potassium and magnesium levels within institutional limits; Serum creatinine below the institutional upper limit of normal (ULN) for age and gender, or creatinine clearance: ≥ 60 mL/min/1.73m2
Liver function
Total bilirubin below the institutional ULN for age; AST/ALT ≤ 2.5 × institutional ULN
Adequate hematologic function defined as: Peripheral absolute neutrophil count ≥ 1,500/µL; Platelet count ≥ 100,000/µL; Partial thromboplastin time (PTT) and activated partial thromboplastin time (APTT): within normal institutional limits. Adequate renal function defined as: Potassium and magnesium levels within institutional limits; Serum creatinine below the institutional upper limit of normal (ULN) for age and gender, or creatinine clearance: ≥ 60 mL/min/1.73m2. Adequate hepatic function defined as: Total bilirubin below the institutional ULN for age; AST/ALT ≤ 2.5 × institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Columbia University Irving Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify